William SumnerJanuary 25, 2018
GW Pharmaceuticals plc (GWPH) is one step closer to bringing its cannabidiol based drug, Epidiolex, to market. On Jan. 24, 2017, the company announced, along with its U.S. subsidiary Greenwich Biosciences, that The Lancet has published results from a Phase 3 study of Epidiolex in patients with Lennox-Gastaut syndrome (LGS). The study’s publication marks the […]